印度-K13突变分析。
An analysis of -K13 mutations in India.
作者信息
Murmu Laxman Kumar, Barik Tapan Kumar
机构信息
P.G. Department of Zoology, Berhampur University, Berhampur, Ganjam, 760007 Odisha India.
出版信息
J Parasit Dis. 2022 Mar;46(1):296-303. doi: 10.1007/s12639-021-01425-7. Epub 2021 Aug 2.
Malaria is one of the deadliest parasitic diseases in human. Currently, Artemisinin-based combination therapy is considered as the gold standard and most common treatment option. However, the origin and transmission of from the Greater Mekong Subregion, which has decreased artemisinin (ART) sensitivity, has sparked global concern. The reduced ART sensitivity has been associated with mutations in the Atpase6 and Kelch13 propeller domain of . A molecular marker is critically needed to monitor the spread of artemisinin resistance. In this article, we reviewed the k13 mutations and potential marker for ART resistance in India. There have been fourteen mutations identified, three of which have been validated by the World Health Organization (WHO) as artemisinin resistance mutations (F446I, R561H/C, and R539T). Among them, the role of F446I and R561H/C in ART resistance is conflicting. R539T and G625R mutation has been identified as an ART- resistance marker in India.
疟疾是人类最致命的寄生虫病之一。目前，以青蒿素为基础的联合疗法被视为金标准和最常用的治疗选择。然而，来自青蒿素敏感性下降的大湄公河次区域的疟疾起源和传播引发了全球关注。青蒿素敏感性降低与疟原虫的Atpase6和Kelch13螺旋桨结构域的突变有关。迫切需要一种分子标记来监测青蒿素耐药性的传播。在本文中，我们综述了印度的k13突变和青蒿素耐药性的潜在标记。已鉴定出14种突变，其中3种已被世界卫生组织（WHO）确认为青蒿素耐药性突变（F446I、R561H/C和R539T）。其中，F446I和R561H/C在青蒿素耐药性中的作用存在争议。R539T和G625R突变已被确定为印度的青蒿素耐药性标记。
Zotero 插件